Alvogen agrees biosimilar commercial deals in three major markets

By Staff Reporter

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Alvogen, Alvotech, Forteo, Eli lilly, Pfenex

Biosimilar developer agrees three different distribution partners in South Korea, Israel and Canada for biosimilar to Forteo.

Alvogen has signed agreements with PharmBio, Kamada and Jamp, for each country, respectively. The company’s biosimilar, PF708, is still subject to approval in the three countries.

The biosimilar was originally developed by Pfenex, but the two companies entered into a development and commercialization agreement​ that would see Alvogen take the lead in certain European countries, the Middle East, North Africa and the ‘rest of world’ territories.

Earlier this month​, PF708 was approved in the US and is known by the brand name, Bonsity. The biosimilar is also currently going through the regulatory process with the European Medicines Agency.

Forteo (teriparatide) is Eli Lilly’s treatment for men and postmenopausal women with osteoporosis. The treatment managed global sales of $1.6bn (€1.4bn) in 2018.

In addition to securing partners in the three countries, Alvogen also noted that it had submitted for marketing authorization in Saudi Arabia.

Alvogen will manufacture the biosimilar out of its subsidiary’s $250m Iceland-based manufacturing plant​.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars